Tuberculosis therapy: past, present and future

Area of Science:

• Medical Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Tuberculosis (TB) treatment has progressed through several key milestones since the 1940s.
• Effective multi-drug regimens have been developed, shortening treatment durations significantly.
• The emergence of drug-resistant TB strains poses a major global health threat.

Purpose of the Study:

• To review the historical advancements in tuberculosis therapy.
• To highlight the challenges posed by drug resistance and treatment noncompliance.
• To emphasize the need for new anti-TB medications and treatment strategies.

Main Methods:

• Historical review of tuberculosis treatment regimens.
• Analysis of the impact of drug discovery on TB cure rates.
• Examination of challenges in TB control, including drug resistance and co-infection with HIV.

Main Results:

• Discovery of streptomycin and PAS in 1944.
• Development of triple therapy (streptomycin, PAS, isoniazid) in 1952.
• Shortened treatment durations to 9 months (isoniazid, rifampin) in the 1970s and 6 months (adding pyrazinamide) in the 1980s.
• Intermittent regimens show promise but face challenges in resource-poor settings.
• Drug-resistant TB strains are a growing concern globally.

Conclusions:

• New anti-TB drugs are crucial to shorten therapy, extend dosing intervals, and overcome resistance.
• Optimal treatment strategies for patients with HIV and TB are needed, considering drug interactions.
• Further research into immune modulation could offer novel approaches to TB treatment.